CLINICAL_TRIALS
trial_result
· 2008-03-27
Clinical Trial Update: A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis [Phase 2]
Summary
A completed Phase 2 trial evaluating 60 mg MM-093 in patients with active rheumatoid arthritis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merrimack Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED